New Drugs and Clinical Trials Amendment Rules 2026: Faster Approvals for Pharma

The Ministry of Health and Family Welfare has notified the New Drugs and Clinical Trials (Amendment) Rules, 2026, introducing significant changes to the regulatory framework governing drug approvals, clinical trials, and non-commercial manufacture in India. The amendment, which became effective on March 7, 2026, refines the New Drugs and Clinical Trials Rules, 2019 by introducing prior-intimation pathways for lower-risk activities and halving the regulatory review timeline from 90 to 45 working days. The changes are part of the government's broader effort to reduce regulatory friction in the pharmaceutical sector and position India as a more competitive destination for clinical research and drug development.

Prior Intimation Pathway for Non-Commercial Manufacture

One of the key changes introduced by the amendment is the creation of a prior-intimation mechanism for non-commercial manufacture of lower-risk drugs. Previously, all manufacturing activities, including those intended solely for analytical testing or non-clinical research, required a full application in Form CT-10 and regulatory approval before commencement. Under the amended rules, manufacture of drugs meant for analytical and non-clinical testing can proceed on the basis of a prior intimation that is acknowledged online by the Central Licensing Authority. This replaces the earlier testing licence requirement for such activities. However, the prior-intimation route is not available for specified high-risk categories. Sex hormones, cytotoxic drugs, beta-lactam antibiotics, biologics containing live microorganisms, and narcotic or psychotropic substances remain subject to the full approval process. The distinction reflects a risk-proportionate regulatory approach.

Halved Review Timelines

The amendment reduces the regulatory review period for clinical trial applications from 90 working days to 45 working days. This is a substantial reduction that brings India's approval timelines closer to those in comparable regulatory jurisdictions. The 90-day timeline had been a persistent point of concern for pharmaceutical companies and clinical research organisations, as delays in trial approval directly affect time-to-market for new drugs and India's attractiveness as a site for global clinical trials. The compressed timeline applies to the CDSCO's review of applications, and the clock starts from the date of a complete submission. Applicants should note that the quality and completeness of the initial application will become even more critical, as any deficiency that requires resubmission will reset the timeline.

Simplified Bioavailability and Bioequivalence Studies

The amendment also streamlines the approval process for certain low-risk Bioavailability (BA) and Bioequivalence (BE) studies. These studies, which are essential for generic drug approvals and are typically lower in risk than full clinical trials, can now proceed under a prior-intimation mechanism rather than requiring prior regulatory approval. This change is expected to accelerate the generic drug pipeline, as BA/BE studies are a routine step in the approval of every generic formulation. The prior-intimation route for BA/BE studies is subject to the same exclusions as the non-commercial manufacture pathway: high-risk drug categories remain outside its scope. The amendment aims to allow the regulator to focus its review resources on genuinely novel and higher-risk applications.

Industry Impact and Competitive Positioning

India is the world's largest supplier of generic medicines by volume and a significant destination for clinical research. However, regulatory timelines have historically been cited as a competitive disadvantage compared to jurisdictions like Singapore, South Korea, and parts of the European Union. The 2026 amendment addresses this directly. Faster approvals are expected to attract more global pharmaceutical companies to conduct clinical trials in India, potentially increasing foreign direct investment in the sector. For domestic generic manufacturers, the streamlined BA/BE process will shorten the development cycle for new formulations. Contract research organisations operating in India stand to benefit from increased trial volumes.

Practical Takeaways

Pharmaceutical companies and CROs should update their regulatory strategy documents and project timelines to reflect the new 45-day review period. Internal SOPs for application preparation should be revised to ensure first-time completeness, as the shorter timeline increases the importance of a clean initial filing. Regulatory affairs teams should identify which of their ongoing or planned activities qualify for the prior-intimation route and transition those accordingly. Companies working with high-risk drug categories should note that the full approval process remains unchanged for them. Legal counsel advising pharma clients should review existing contracts and collaboration agreements to determine whether the new timelines affect any milestone-based obligations.